歌礼制药-B在第61届欧洲糖尿病研究协会年会上公布口服小分子GLP-1R激动剂ASC30临床试验数据

美股速递
Sep 17, 2025

歌礼制药-B在第61届欧洲糖尿病研究协会(EASD)年会上展示了其口服小分子GLP-1R激动剂ASC30的28天多剂量递增研究结果。

此次公布的数据涵盖了该项研究第1队列和第2队列的试验成果。ASC30作为一款创新的口服小分子GLP-1受体激动剂,代表了歌礼制药-B在糖尿病治疗领域的重要布局。

该研究采用28天多剂量递增的设计方案,旨在评估ASC30的安全性、耐受性和药代动力学特征,为后续临床开发提供重要数据支撑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10